A Lifecourse Map of Diseases in China

A Lifecourse Map of Common Diseases and Rare Diseases in China

The purpose of this study is to form a chronological map of common diseases and rare diseases in Chinese population by determining the prevalence of different diseases in each age group.

Study Overview

• Status: Recruiting
• Conditions: Rare Diseases; Common Diseases
• Intervention / Treatment: Other: Data analysis

Detailed Description

Studying the distribution of various diseases in specific populations can help explore the causes of diseases, elucidate the distribution patterns, and develop preventive and control measures. Based on an overall assessment of prevalence, the combination of relevant results with age at diagnosis for multiple diseases is important for further understanding of the distribution of diseases at the population level. Therefore, this study aims to form a chronological map of common diseases and rare diseases in Chinese population by determining the prevalence of different diseases in each age group, thus providing a reference for more effective prevention, diagnosis and treatment of diseases.

• Study Type: Observational
• Enrollment (Anticipated): 40000000

Contacts and Locations

Study Locations

• China
  • Shandong
    • Jinan, Shandong, China, 250012
      • Recruiting
      • Shandong University
      • Contact: Wei Zhao, Ph.D; Phone Number: 15131190710; Email: zhao4wei2@hotmail.comzhao

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: ADULT; OLDER_ADULT; CHILD
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

All inpatients within the period of January 1, 2017 to December 31, 2021.

Description

Inclusion Criteria:

1. All inpatients within the period of January 1, 2017 to December 31, 2021.
2. Patients with discharge diagnosis.
3. Patients with accurate gender and age records.

Exclusion Criteria:

1. Morbidity and mortality due to external causes, i.e. injuries, poisonings and other adverse events due to external environment and accidents.
2. Pregnancy-related conditions.
3. Symptoms, signs, abnormal clinical and laboratory findings.
4. Traditional Chinese Medicine diagnosis records.
5. Patients with incorrect or missing disease codes.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Hospitalized patients; The diseases were included based on the results of the preliminary data exploration and standardization according to ICD-10.	Other: Data analysis; Data analysis is based on a single database from the National Health Medical Data (North Center).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
age-specific prevalence rate	Age-specific prevalence rate stratified by sex were calculated by dividing the number of incident cases with a current disease by the total number of people in the study population during that time period.	between January 1, 2017 and December 31, 2021
sex-specific prevalence rate	Sex-specific prevalence rate stratified by age for 10-year bands were calculated by dividing the number of incident cases with a current disease by the total number of people in the study population during that time period.	between January 1, 2017 and December 31, 2021

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
total cost of hospitalization	Total cost of hospitalization and deductibles for the total population and for each age group of diseases are described by mean (SD) values.	between January 1, 2017 and December 31, 2021

Collaborators and Investigators

• Sponsor: Shandong University
• Collaborators: National Health Medical Data (North Center)

Study record dates

Study Major Dates

• Study Start (ACTUAL): August 1, 2022
• Primary Completion (ANTICIPATED): July 31, 2023
• Study Completion (ANTICIPATED): July 31, 2024

Study Registration Dates

• First Submitted: November 3, 2022
• First Submitted That Met QC Criteria: November 3, 2022
• First Posted (ACTUAL): November 10, 2022

Study Record Updates

• Last Update Posted (ACTUAL): November 10, 2022
• Last Update Submitted That Met QC Criteria: November 3, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Rare Diseases
• Other Study ID Numbers: 2022-DISEASE

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No